Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.

被引：7
|
作者：
O'Malley, David M.
Moore, Kathleen N.
Vergote, Ignace
Martin, Lainie P.
Gilbert, Lucy
Martin, Antonio Gonzalez
Nepert, Dale L.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
Matulonis, Ursula A.
机构：
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[3] Univ Leuven, Leuven Canc Inst, Leuven, Belgium
[4] BGOG, Leuven, Belgium
[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[7] Grupo Espanol Invest Canc Ovario GEICO, Madrid, Spain
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] ImmunoGen Inc, Waltham, MA USA
[10] Massachusetts Gen Hosp, Boston, MA 02114 USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.5553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5553
引用
收藏
页数：4
相关论文
共 28 条
  • [21] Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
    Moore, Kathleen N.
    Martin, Lainie P.
    Seward, Shelly Marie
    Bauer, Todd Michael
    O'Malley, David M.
    Perez, Raymond P.
    Oza, Amit M.
    Jeong, Woondong
    Kirby, Maurice William
    Zhou, Yinghui
    Michenzie, Mary F.
    Ponte, Joseph
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples in a phase I study of mirvetuximab soravtansine, a FRα-targeting antibody-drug conjugate (ADC), in relapsed epithelial ovarian cancer patients
    Martin, L. P.
    Konner, J.
    Moore, K. N.
    Seward, S. M.
    Matulonis, U. A.
    Perez, R. P.
    Zhou, Y.
    Ponte, J.
    Zhao, J.
    Ruiz-Soto, R.
    Birrer, M. J.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 34 - 34
  • [23] FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
    Moore, K.
    Oza, A.
    Colombo, N.
    Oaknin, A.
    Scambia, G.
    Lorusso, D.
    Farias-Eisner, R.
    Banerjee, S.
    Murphy, C.
    Tanyi, J.
    Hirte, H.
    Konner, J.
    Lim, P.
    Hayes, M. Prasad
    Monk, B.
    Kim, S.
    Wang, J.
    Pautier, P.
    Vergote, I.
    Birrer, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
    Matulonis, U. A.
    Moore, K. N.
    Martin, L. P.
    Vergote, I. B.
    Castro, C. M.
    Gilbert, L.
    Berkenblit, A.
    Birrer, M. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
  • [25] Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
    Martin, Lainie P.
    Konner, Jason A.
    Moore, Kathleen N.
    Seward, Shelly M.
    Matulonis, Ursula A.
    Perez, Raymond P.
    Su, Ying
    Berkenblit, Anna
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 402 - 407
  • [26] FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
    Moore, Kathleen N.
    Vergote, Ignace
    Oaknin, Ana
    Colombo, Nicoletta
    Banerjee, Susana N.
    Oza, Amit M.
    Pautier, Patricia
    Kelly, Catherine Margaret
    Malek, Karim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
    Banerjee, Susana N.
    Oza, Amit M.
    Birrer, Michael J.
    Hamilton, Erika Paige
    Hasan, Jurjees
    Leary, Alexandra
    Moore, Kathleen N.
    Mackowiak-Matejczyk, Beata
    Pikiel, Joanna
    Ray-Coquard, Isabelle
    Trask, Peter
    Lin, Kedan
    Vaze, Anjali
    Choi, YounJeong
    Marsters, Jim
    Maslyar, Daniel J.
    Lemahieu, Vanessa
    Wang, Yulei
    Humke, Eric William
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers).
    Naumann, R. Wendel
    Martin, Lainie P.
    Oaknin, Ana
    Spira, Alexander I.
    Hamilton, Erika P.
    Schilder, Russell J.
    Lu, Lin
    Kuriakose, Jason
    Berman, Craig Jerome
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
123